Atorvaliq is owned by Cmp Dev Llc.
Atorvaliq contains Atorvastatin Calcium.
Atorvaliq has a total of 1 drug patent out of which 0 drug patents have expired.
Atorvaliq was authorised for market use on 01 February, 2023.
Atorvaliq is available in suspension;oral dosage forms.
The generics of Atorvaliq are possible to be released after 07 June, 2037.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US11369567||CMP DEV LLC||Aqueous suspension suitable for oral administration|| |
(14 years from now)
Drugs and Companies using ATORVASTATIN CALCIUM ingredient
Market Authorisation Date: 01 February, 2023
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic